Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended December 31, 2024, and the nine months ended December 31, 2024. Sonoma Pharmaceuticals is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye care, and animal health. The company operates in 55 countries, manufacturing all goods in Mexico. On August 29, 2024, the company effected a 20-for-1 reverse stock split.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 31, 2024 | 9 Months Ended Dec 31, 2024 | 9 Months Ended Dec 31, 2023 |
|---|---|---|---|
| Revenues | $3,564 | $10,534 | $9,296 |
| Gross Profit | $1,270 | $3,937 | $3,654 |
| Gross Margin | 36% | 37% | 39% |
| Net Loss | $(928) | $(2,681) | $(3,768) |
| Net Loss Per Share (Basic/Diluted) | $(0.63) | $(2.40) | $(10.74) |
| Cash and Cash Equivalents | $5,236 (Dec 31, 2024) | $5,236 (Dec 31, 2024) | $2,406 (Dec 31, 2023) |
| Working Capital | $8,677 (Dec 31, 2024) | $8,677 (Dec 31, 2024) | $9,428 (Dec 31, 2023) |
| Short-Term Debt | $0 | $0 | $323 (Mar 31, 2024) |
| Operating Cash Flow (9 Months) | N/A | $7 | $(2,550) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 14% ($426k) for the quarter and 13% ($1.24M) for the nine months compared to the prior year periods.
- Geographic Shifts: Latin America revenue surged 125% ($461k) in the quarter and 87% ($1.01M) for the nine months, driven by increased manufacturing orders. Conversely, U.S. revenue declined 29% ($254k) in the quarter and 13% ($284k) for the nine months due to fluctuations in animal health product demand.
- Margin Compression: Gross margin decreased from 47% to 36% in the quarter and from 39% to 37% for the nine months. This was attributed to prior period utilization of manufacturing resources for European regulatory requirements being reported in R&D, whereas current year costs were lower.
- Loss Reduction: Net loss improved significantly on a per-share basis due to the reverse stock split and reduced absolute losses ($2.68M vs $3.77M for the nine months).
- Capital Raise: The company raised $3.08 million in net proceeds from the sale of common stock via an At-the-Market (ATM) program during the nine months ended December 31, 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern within one year due to a history of losses and the need for additional capital. Financial statements do not include adjustments that might be necessary if the company cannot continue.
- Tariff Risks: The company manufactures all goods in Mexico. Recent announcements of potential U.S. tariffs on goods from Mexico (up to 25%) and Canada pose a risk. While current U.S. sales are only 18% of total revenue, future growth in the U.S. market could make tariffs material.
- Regulatory Compliance: The company faces risks related to the transition of European products to the new Medical Device Regulation (MDR). Failure to obtain CE markings by December 31, 2028, could result in product withdrawal from the EU market.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of December 31, 2024, due to material weaknesses, specifically a lack of separation of duties in financial reporting. Remediation efforts are underway.
- Strategic Partnerships: In August 2024, the company entered a distribution agreement with Medline Industries, LP for the U.S. and Canada, and signed a master supply agreement with WellSpring Pharmaceutical Corporation in January 2025.
Investor Verification Checklist
- Verify the timeline and sufficiency of capital raised to address the "substantial doubt" regarding going concern status.
- Monitor the impact of potential U.S. tariffs on Mexican goods on the company's cost structure and U.S. sales growth.
- Review the progress of remediation for material weaknesses in internal controls over financial reporting.
- Assess the status of European MDR compliance for products currently under review (e.g., Ocudox, GramaDerm).
- Confirm the performance of new distribution agreements with Medline and WellSpring in driving U.S. revenue recovery.